Business Context and Reporting Period
Company: Harvard Bioscience, Inc. (HBIO)
Filing Type: Form 8-K (Current Report)
Date of Report: December 17, 2025
Event: Entry into a Material Definitive Agreement (Loan and Security Agreement) and termination of a prior credit facility.
Key Financial Metrics and Debt Structure
The filing details a new financing arrangement totaling $40.0 million in principal, structured as follows:
- Term A Loan: $10.0 million (Senior Secured).
- Term B Loan: $22.5 million (Senior Secured).
- Term C Loan: $7.5 million (Senior Secured Convertible).
Interest Rates: The greater of (i) 12.80% for the first two years (then 12.50%) or (ii) Prime Rate + 5.25%. Interest on Term C may be paid in kind at the Company's option.
Use of Proceeds: Repayment of the prior credit facility (Citizens Bank, N.A.), transaction fees, and working capital.
Equity Dilution: Issuance of warrants to purchase 2,000,000 shares of Common Stock at an exercise price of $0.50 per share.
Material Changes Versus Prior Period
- Debt Restructuring: The Company terminated its prior term loan and senior revolving credit facility with Citizens Bank, N.A. effective December 17, 2025.
- Board Composition: Appointment of Mr. William A. Snider (BroadOak partner) to the Board of Directors and Compensation Committee.
- Covenants: Implementation of new financial covenants, including a minimum liquidity covenant (tested continuously) and a minimum Adjusted EBITDA covenant (tested quarterly).
Guidance, Outlook, and Risks
Management Commentary and Governance:
- The Administrative Agent (BroadOak) has the right to nominate one board member while the loans are outstanding.
- The Company must establish a Product, Operations, and Scientific Advisory Board by March 31, 2026, with two members appointed by the Administrative Agent.
Key Risks and Contingencies:
- Prepayment Penalties: Significant prepayment premiums apply (3.00% in year 1, 2.00% in year 2, 1.00% in year 3) and a 10.00% exit fee on prepaid amounts (excluding converted Term C loans).
- Conversion Triggers: Term C loans convert automatically if the share price exceeds $1.50 for 30 consecutive trading days.
- Restrictions: Negative covenants limit the ability to incur additional debt, pay dividends, or sell assets.
Financial Performance: The filing text does not provide specific revenue, profit, cash flow, or margin figures for the current or prior periods.
Investor Verification Checklist
- Verify the exact amount of debt repaid from the prior Citizens Bank facility to confirm net cash proceeds.
- Confirm the current Adjusted EBITDA and liquidity levels to assess immediate covenant compliance.
- Review the registration statement filing timeline for the 2,000,000 warrant shares and convertible Term C loan shares.
- Monitor the stock price relative to the $1.50 automatic conversion trigger for the Term C Loan.
- Assess the impact of the 10.00% exit fee on future refinancing or prepayment strategies.